These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

730 related items for PubMed ID: 17472599

  • 21. A comparative study of the efficacy of long-term treatment with escitalopram and paroxetine in severely depressed patients.
    Boulenger JP, Huusom AK, Florea I, Baekdal T, Sarchiapone M.
    Curr Med Res Opin; 2006 Jul; 22(7):1331-41. PubMed ID: 16834832
    [Abstract] [Full Text] [Related]

  • 22. Duloxetine versus placebo in the treatment of major depressive disorder and associated painful physical symptoms: a replication study.
    Gaynor PJ, Gopal M, Zheng W, Martinez JM, Robinson MJ, Hann D, Marangell LB.
    Curr Med Res Opin; 2011 Oct; 27(10):1859-67. PubMed ID: 21838410
    [Abstract] [Full Text] [Related]

  • 23. Resolution of sexual dysfunction during double-blind treatment of major depression with reboxetine or paroxetine.
    Baldwin D, Bridgman K, Buis C.
    J Psychopharmacol; 2006 Jan; 20(1):91-6. PubMed ID: 16204325
    [Abstract] [Full Text] [Related]

  • 24. Time course of depression-symptom improvement during treatment with duloxetine.
    Hirschfeld RM, Mallinckrodt C, Lee TC, Detke MJ.
    Depress Anxiety; 2005 Jan; 21(4):170-7. PubMed ID: 16035056
    [Abstract] [Full Text] [Related]

  • 25. Safety and tolerability of duloxetine at 60 mg once daily in elderly patients with major depressive disorder.
    Raskin J, Wiltse CG, Dinkel JJ, Walker DJ, Desaiah D, Katona C.
    J Clin Psychopharmacol; 2008 Feb; 28(1):32-8. PubMed ID: 18204338
    [Abstract] [Full Text] [Related]

  • 26. Anxiety does not predict response to duloxetine in major depression: results of a pooled analysis of individual patient data from 11 placebo-controlled trials.
    Nelson JC.
    Depress Anxiety; 2010 Feb; 27(1):12-8. PubMed ID: 20013987
    [Abstract] [Full Text] [Related]

  • 27. Efficacy and safety of duloxetine in the treatment of generalized anxiety disorder: a flexible-dose, progressive-titration, placebo-controlled trial.
    Rynn M, Russell J, Erickson J, Detke MJ, Ball S, Dinkel J, Rickels K, Raskin J.
    Depress Anxiety; 2008 Feb; 25(3):182-9. PubMed ID: 17311303
    [Abstract] [Full Text] [Related]

  • 28. Efficacy, safety, and tolerability of fixed-dose desvenlafaxine 50 and 100 mg/day for major depressive disorder in a placebo-controlled trial.
    Boyer P, Montgomery S, Lepola U, Germain JM, Brisard C, Ganguly R, Padmanabhan SK, Tourian KA.
    Int Clin Psychopharmacol; 2008 Sep; 23(5):243-53. PubMed ID: 18703933
    [Abstract] [Full Text] [Related]

  • 29. A multicenter double-blind comparison of nefazodone and paroxetine in the treatment of outpatients with moderate-to-severe depression.
    Baldwin DS, Hawley CJ, Abed RT, Maragakis BP, Cox J, Buckingham SA, Pover GH, Ascher A.
    J Clin Psychiatry; 1996 Sep; 57 Suppl 2():46-52. PubMed ID: 8626363
    [Abstract] [Full Text] [Related]

  • 30. Duloxetine in treatment of anxiety symptoms associated with depression.
    Dunner DL, Goldstein DJ, Mallinckrodt C, Lu Y, Detke MJ.
    Depress Anxiety; 2003 Sep; 18(2):53-61. PubMed ID: 12964171
    [Abstract] [Full Text] [Related]

  • 31. Efficacy and tolerability of escitalopram versus citalopram in major depressive disorder: a 6-week, multicenter, prospective, randomized, double-blind, active-controlled study in adult outpatients.
    Yevtushenko VY, Belous AI, Yevtushenko YG, Gusinin SE, Buzik OJ, Agibalova TV.
    Clin Ther; 2007 Nov; 29(11):2319-32. PubMed ID: 18158074
    [Abstract] [Full Text] [Related]

  • 32. Long-term tolerability and effectiveness of duloxetine in the treatment of major depressive disorder.
    Dunner DL, Wilson M, Fava M, Kornstein S, Munoz R, O'Reardon J, Trivedi M, Wohlreich M.
    Depress Anxiety; 2008 Nov; 25(5):E1-8. PubMed ID: 17621644
    [Abstract] [Full Text] [Related]

  • 33. Duloxetine 60 mg once-daily in the treatment of painful physical symptoms in patients with major depressive disorder.
    Brannan SK, Mallinckrodt CH, Brown EB, Wohlreich MM, Watkin JG, Schatzberg AF.
    J Psychiatr Res; 2005 Jan; 39(1):43-53. PubMed ID: 15504423
    [Abstract] [Full Text] [Related]

  • 34. Comparisons of the efficacy and tolerability of extended-release venlafaxine, mirtazapine, and paroxetine in treatment-resistant depression: a double-blind, randomized pilot study in a Chinese population.
    Fang Y, Yuan C, Xu Y, Chen J, Wu Z, Cao L, Yi Z, Hong W, Wang Y, Jiang K, Gao K, Cui X, Nierenberg AA, OPERATION Study Team.
    J Clin Psychopharmacol; 2010 Aug; 30(4):357-64. PubMed ID: 20571433
    [Abstract] [Full Text] [Related]

  • 35. Acute and long-term treatment of late-life major depressive disorder: duloxetine versus placebo.
    Robinson M, Oakes TM, Raskin J, Liu P, Shoemaker S, Nelson JC.
    Am J Geriatr Psychiatry; 2014 Jan; 22(1):34-45. PubMed ID: 24314888
    [Abstract] [Full Text] [Related]

  • 36. [Comparative study of paroxetine and mianserin in depression in elderly patients: efficacy, tolerance, serotonin dependence].
    Daléry J, Aubin V.
    Encephale; 2001 Jan; 27(1):71-81. PubMed ID: 11294041
    [Abstract] [Full Text] [Related]

  • 37. Clinical milestones predict symptom remission over 6-month and choice of treatment of patients with major depressive disorder (MDD).
    Wade AG, Schlaepfer TE, Andersen HF, Kilts CD.
    J Psychiatr Res; 2009 Feb; 43(5):568-75. PubMed ID: 18954875
    [Abstract] [Full Text] [Related]

  • 38. A randomized controlled trial of duloxetine versus placebo in the treatment of nonmajor chronic depression.
    Hellerstein DJ, Stewart JW, McGrath PJ, Deliyannides DA, Batchelder ST, Black SR, Withers A, O'Shea D, Chen Y.
    J Clin Psychiatry; 2012 Jul; 73(7):984-91. PubMed ID: 22901348
    [Abstract] [Full Text] [Related]

  • 39. Predictors of relapse in a study of duloxetine treatment in patients with major depressive disorder.
    Fava M, Wiltse C, Walker D, Brecht S, Chen A, Perahia D.
    J Affect Disord; 2009 Mar; 113(3):263-71. PubMed ID: 18625521
    [Abstract] [Full Text] [Related]

  • 40. Use of effect size to determine optimal dose of duloxetine in major depressive disorder.
    Pritchett YL, Marciniak MD, Corey-Lisle PK, Berzon RA, Desaiah D, Detke MJ.
    J Psychiatr Res; 2007 Mar; 41(3-4):311-8. PubMed ID: 16934840
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 37.